Pilot, randomized trial of resistance exercise during radiation therapy for head and neck cancer. Issue 8 (30th July 2012)

• Record Type: Journal Article
• Authors: Rogers, Laura Q.; Anton, Philip M.; Fogleman, Amanda; Hopkins–Price, Patricia; Verhulst, Steven; Rao, Krishna; Malone, James; Robbs, Randy; Courneya, Kerry S.; Nanavati, Parashar; Mansfield, Sara; Robbins, K. Thomas
• Is Part Of: Head & neck. Volume 35:Issue 8(2013:Aug.)
• Page Start: 1178
• Page End: 1188
• Publication Date: 2012-07-30
• Subjects: Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.23118
• Languages: English
• ISSNs: 1043-3074

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="abs1-1" sec-type="section"> <title>Background</title> <p>The purpose of this study was to determine the feasibility of a randomized trial of resistance exercise in patients with head and neck cancer receiving radiation.</p> </sec> <sec id="abs1-2" sec-type="section"> <title>Methods</title> <p>Fifteen patients with head and neck cancer receiving radiation were randomized to resistance exercise (using resistance bands) or control group. Resistance exercise occurred at the radiation therapy site (weeks 1–6) and home (weeks 7–12).</p> </sec> <sec id="abs1-3" sec-type="section"> <title>Results</title> <p>No serious adverse events occurred related to resistance exercise. Medium to large effect size differences favoring resistance exercise versus control group were noted for perceived fatigue at 6 weeks (smaller increase in fatigue for resistance exercise group; 7.4 vs 15.4, effect size [<italic>d</italic>] = −0.64), quality of life at 6 weeks (−7.0 vs −14.4, <italic>d</italic> = 0.52), and chair rise time (seconds) at 6 and 12 weeks (−1.6 vs 0.4, <italic>d</italic> = −.63 and −1.9 vs 0.1, <italic>d</italic> = −0.60, respectively).</p> </sec> <sec id="abs1-4" sec-type="section"> <title>Conclusions</title> <p>Resistance exercise is safe and feasible in patients with head and neck cancer receiving radiation; a definitive trial is warranted. © 2012 Wiley Periodicals, Inc. Head Neck, 2013</p> </sec> </abstract>